European ethics board approval

Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection

February 16, 2021March 22, 2021globalstocksnews

VANCOUVER, BC – Lexaria Bioscience’s (LEXX.NASDAQ) (LEXX.CSE) drug delivery technology, DehydraTECHTM improves the “bioavailability” of pharmaceutical ingredients. “Bioavailability is the rate and extent [...]